Antibodies
8 June 2009
Seattle Genetics Reports Data from SGN-35 Every Three Week Dosing Phase I Trial in Lymphoma8 June 2009
Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes8 June 2009
XOMA 052 Clinical Results Support Novel Anti-Inflammatory Approach to Type 2 Diabetes Treatment5 June 2009
Immunomedics Reports Updated Results of Low-Dose Veltuzumab for Immune Thrombocytopenic Purpura2 June 2009
CuraGen Updates CR011-vcMMAE Data at ASCO1 June 2009
Seattle Genetics Reports Data from a Weekly Dosing Phase I Clinical Trial of SGN-35 in Lymphoma31 May 2009
Novel Targeted Radiation Therapy From Immunomedics Produces Objective Responses in Pancreatic Cancer31 May 2009
Genentech Announces Full Results from First Phase III Study of Avastin in Early-Stage Colon Cancer30 May 2009
ImmunoGen, Inc. Announces Encouraging Trastuzumab-DM1 Phase II Clinical Findings Presented at ASCO30 May 2009
Pfizer Data Identify Certain Lung Cancer Patients Who May Benefit from Treatment with FigitumumabNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports